https://doi.org/10.4081/reumatismo.2024.1658
Systemic lupus erythematosus induced by anti-tumor necrosis factor α therapy in inflammatory rheumatic diseases: a case series
Accepted: 3 May 2024
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
This case series aims to characterize the development of systemic lupus erythematosus (SLE) induced by anti-tumor necrosis factor α (anti-TNFα) therapy in patients with inflammatory rheumatic diseases, namely rheumatoid arthritis (RA), spondylarthritis (SpA), and psoriatic arthritis (PsA). Patients with a diagnosis of SLE induced by anti-TNFα therapy and registered on the Rheumatic Diseases Portuguese Register (Reuma.pt) who started their first anti-TNFα between 2001 and 2020 were included. Demographic, clinical, and laboratory data were obtained by consulting Reuma.pt. The diagnosis of SLE induced by anti-TNFα was considered if there was a temporal relationship between the onset of anti-TNFα therapy and manifestations (clinical and immunological) in accordance with the American College of Rheumatology/European League Against Rheumatism criteria (2019). A total of 607 patients with inflammatory rheumatic diseases and six cases of SLE induced by anti-TNF-α therapy were reviewed: two patients were affected by RA, three patients by SpA, and one by PsA. All these patients had articular and constitutional symptoms that improved after discontinuation of the anti-TNFα agent. After switching to a second anti-TNFα agent, there was no recurrence of SLE over time. The development of SLE secondary to anti-TNFα agents in inflammatory rheumatic patients is rare. In this case series, all patients had a mild disease that improved after therapy discontinuation without recurrence of the disease. SLE induced by anti-TNFα should be considered in the follow-up of RA, SpA, and PsA patients.
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
Similar Articles
- G. Pasero, P. Marson, A short history of anti-rheumatic therapy. II. Aspirin , Reumatismo: Vol. 62 No. 2 (2010)
- Luca Idolazzi, A. Fassio, D. Gatti, S. Tamanini, O. Viapiana, M. Rossini, S. Adami, Duration of treatment for osteoporosis , Reumatismo: Vol. 65 No. 1 (2013)
- E. Di Poi, M. Bombardieri, R. Damato, E. Gremese, G. Valesini, GF. Ferraccioli, Neurological involvement in systemic sclerosis. Evidence of a central Raynaud’s phenomenon , Reumatismo: Vol. 53 No. 4 (2001)
- H.K. Aggarwal, D. Jain, A. Mittal, G. Dabas, Isolated oculocutaneous sarcoidosis in a teenage male: a rare case report , Reumatismo: Vol. 68 No. 2 (2016)
- F. Muratore, C. Salvarani, P. Macchioni, Contribution of the new 2012 EULAR/ACR classification criteria for the diagnosis of polymyalgia rheumatica , Reumatismo: Vol. 70 No. 1 (2018): Monographic issue on Polymyalgia Rheumatica
- E. Catarsi, M. Doveri, A. Tavoni, Bosentan and sildenafil: successful treatment in a sclerodermic patient with refractory ulcers , Reumatismo: Vol. 65 No. 2 (2013)
- C. Palazzi, I. Olivieri, C. Salvarani, E. D'Amico, G. Alleva, P. Vitullo, A. Petricca, Reactive arthritis: advances in diagnosis and treatment , Reumatismo: Vol. 54 No. 2 (2002)
- N. Franzolini, L. Quartuccio, G. De Marchi, S. De Vita, Efficacy of immunosoppressive therapy and steroid sparing effect in interstitial lung disease associated to antisynthetase syndrome , Reumatismo: Vol. 59 No. 3 (2007)
- T. Maio, P. Trezzi, M.A. Cimmino, Pure analgesics in a rheumatological outpatient clinic , Reumatismo: Vol. 53 No. 2 (2001)
- A. Mastroianni, F. Allegrini, S. Nardi, D. Donatucci, F. Girelli, C. Guidi, Carpal tunnel syndrome in HIV-positive patients coinfected with HCV , Reumatismo: Vol. 69 No. 4 (2017)
<< < 41 42 43 44 45 46 47 48 49 50 > >>
You may also start an advanced similarity search for this article.
